Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Morris Roebuck

Internal Medicine Birmingham, AL Medical Doctor

NPI 1356554620 CMS profile 107432

833 Saint Vincents Dr Ste 300, Pob III, Birmingham, AL 35205

Open in the dashboard

General payments

$12,426

720 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Morris Roebuck of Birmingham, AL is reported in the CMS Open Payments database as having received $12,426 across 720 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,493 76
2024 General $1,491 78
2023 General $1,466 88
2022 General $1,920 113
2021 General $2,349 140
2020 General $2,107 127
2019 General $1,599 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Morris Roebuck
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Morris Roebuck were reported at $1,493. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Morris Roebuck Internal Medicine median Middle half National median
2019 $1,599 $159 $48–$570 $163
2020 $2,107 $119 $33–$402 $114
2021 $2,349 $135 $37–$521 $132
2022 $1,920 $141 $42–$496 $149
2023 $1,466 $149 $45–$519 $160
2024 $1,491 $154 $47–$537 $164
2025 $1,493 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,749 100 payments
  2. Pfizer Inc. $1,268 68 payments
  3. Lilly USA, LLC $1,245 71 payments
  4. Amgen Inc. $1,013 64 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $908 54 payments
  6. Novo Nordisk Inc $808 44 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $708 46 payments
  8. AstraZeneca Pharmaceuticals LP $684 39 payments
  9. GlaxoSmithKline, LLC. $621 38 payments
  10. E.R. Squibb & Sons, L.L.C. $390 25 payments
  11. Other $3,033 171 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,416 718 payments
  2. Education $10 2 payments
Products named General payments · program years 2019–2025
  1. Kerendia $908 54 payments
  2. ELIQUIS $825 42 payments
  3. RINVOQ $695 35 payments
  4. Ozempic $603 33 payments
  5. MOUNJARO $575 30 payments
  6. RYBELSUS $572 31 payments
  7. FARXIGA $539 32 payments
  8. JARDIANCE $487 33 payments
  9. HUMIRA $399 22 payments
  10. BENLYSTA $393 24 payments
  11. Other $10,892 642 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 147 drugs

Part D claims

11,836

Median for Internal Medicine: 777

Drug cost

$977,822

Median for Internal Medicine: $73,373

Branded share of claims

21.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 313 $213,906
Jardiance Empagliflozin Brand 157 $143,162
Ozempic Semaglutide Brand 96 $84,904
Mounjaro Tirzepatide Brand 69 $81,177
Trulicity Dulaglutide Brand 49 $63,920
Synjardy Empagliflozin/Metformin Hcl Brand 48 $37,224
Xarelto Rivaroxaban Brand 44 $33,160
Synjardy Xr Empagliflozin/Metformin Hcl Brand 35 $21,006
Creon Lipase/Protease/Amylase Brand 14 $20,639
Breo Ellipta Fluticasone/Vilanterol Brand 39 $18,902

The 10 drugs with the highest cost, of 147 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 141 billing codes

Paid by Medicare

$225,052

Of which drugs: $50,872

Medicare patients

288

Average age 77

Services billed

14,441

150 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Chronic kidney disease 35%
Diabetes 30%
Depression 26%
Atrial fibrillation 19%
Cancer 19%
Ischemic heart disease 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 63 63 $17,364
Vaccine for influenza for injection into muscle 90653 Office 94 94 $7,609
Sarscv2 vac 30mcg trs-suc im 91320 Office 17 17 $2,324
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 14 1,500 $156

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$212 157 —
MOUNJARO
$195 69 —
Kerendia
$148 — —
RYBELSUS
$98 — —
Ozempic
$98 96 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

720 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record